September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Two Phase 3 studies of the efficacy and safety of AR-13324 Ophthalmic Solution 0.02%: in Patients with Open Angle Glaucoma and Ocular Hypertension
Author Affiliations & Notes
  • L Jay Katz
    Glaucoma, Wills Eye, Philadelphia, Pennsylvania, United States
  • Mark J. Weiss
    The Eye Institute, Tulsa, Oklahoma, United States
  • Theresa Heah
    Aerie Pharmaceuticals, Bedminster, California, United States
  • Casey Kopczynski
    Aerie Pharmaceuticals, Research Triangle Park, North Carolina, United States
  • Gary D Novack
    PharmaLogic Development, Inc., San Rafael, California, United States
    Pharmacology & Ophthalmology, University of California, Davis, California, United States
  • Footnotes
    Commercial Relationships   L Jay Katz, Aerie Pharmaceuticals (I), Aerpio (C), Alimera (C), Allergan (C), Bausch + Lomb (C), Diopsys (C), Forsight Vision V (C), Glaukos (I), Heidelberg (F), Innfocus (C), Inotek (C), Mati (I), Ocular therapeutix (C), Sensimed (C); Mark Weiss, Aerie Pharmaceuticals (F); Theresa Heah, Aerie Pharmaceuticals (E); Casey Kopczynski, Aerie Pharmaceuticals (E); Gary Novack, Aerie Pharmaceuticals (C), Envisia (C), ForSight Vision5 (C), Peregrine (C), Polyactiva (C), Teva (C)
  • Footnotes
    Support  Aerie Pharmaceuticals
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      L Jay Katz, Mark J. Weiss, Theresa Heah, Casey Kopczynski, Gary D Novack; Two Phase 3 studies of the efficacy and safety of AR-13324 Ophthalmic Solution 0.02%: in Patients with Open Angle Glaucoma and Ocular Hypertension. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : We compared the ocular hypotensive efficacy and safety of AR-13324 Ophthalmic Solution 0.02% to timolol ophthalmic solution 0.5% BID in patients with elevated intraocular pressure (IOP) (open angle glaucoma and ocular hypertension) in two Phase 3 studies Rocket 1 and Rocket 2 (R1, R2). AR-13324 inhibits both Rho kinase and the norepinephrine transporter and increases trabecular outflow, reduces aqueous humor formation, and decreases episcleral venous pressure in preclinical models.

Methods : Subjects with baseline IOP >20 and <27 mmHg (in R1), and >20 and <25 mm Hg (in R2), were included in the primary efficacy analysis. In R1, patients were randomized to receive either AR-13324 0.2% QD (PM) or timolol 0.5% BID for 3 months, R2 was a 12 month study where AR-13324 0.2% was dosed QD and BID. In both studies, the efficacy endpoint was mean IOP at 8:00, 10:00, and 16:00 hours at Weeks 2, 6, and Month 3.

Results : A total of 411 subjects in R1 and 756 subjects in R2 were randomized. While AR-13324 0.2% QD did not meet the criteria for non-inferiority to timolol 0.5% BID in subjects with baseline IOP <27 mmHg in R1, it was non-inferior to timolol 0.5% BID in a pre-specified analysis of subjects with baseline IOPs of ≤23 mmHg and in a post hoc analysis of subjects with baseline IOP <25 mmHg. In Rocket 2, both regimens of AR-13324 0.2% were non-inferior to timolol 0.5% BID in the primary population (baseline IOP < 25 mmHg). The most common safety finding was conjunctival hyperemia, which was of mild severity in a majority of subjects. The BID dosing regimen of AR-13324 resulted in more ocular adverse events and treatment discontinuations than QD dosing.

Conclusions : AR-13324 0.2%, dosed QD and BID, was non-inferior to timolol 0.5% BID in subjects with baseline pressures below 25 mmHg, with a better safety and tolerability profile with QD dosing.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×